Collectively, these findings establish endothelial LOX/LOXL2 as core regulators of pathogenic glomerular signaling in diabetes and position Verbascoside as an enzymatically targeted precision therapy for DKD acting through the disruption of this specific LOX/LOXL2-mediated axis. Here, LOXL2 is linked to diabetes mellitus.